---
schema_version: "secwatch.filing_event.v1"
accession: "0001808805-22-000044"
form_type: "8-K"
ticker: "NAUT"
cik: "0001808805"
company_name: "Nautilus Biotechnology, Inc."
filed_at: "2022-05-03T23:59:59+00:00"
generated_at: "2026-06-26T01:37:04.851866+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Nautilus Biotechnology Q1 net loss widens to $15.8M on higher R&D and G&A costs

## Summary
- Operating expenses $16.0M, up 90% YoY from $8.4M, driven by headcount and public company costs.
- Net loss $15.8M vs $8.4M in prior year; no revenue reported (pre-revenue proteomics platform).
- Cash, cash equivalents, and investments $349.0M as of March 31, 2022.
- Scientific progress: manuscript on single-molecule protein arrays, Genentech collaboration results, and AACR antibody data.

## SEC filing metadata
- accession: 0001808805-22-000044
- form_type: 8-K
- ticker: NAUT
- cik: 0001808805
- company_name: Nautilus Biotechnology, Inc.
- filed_at: 2022-05-03T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1808805/000180880522000044/0001808805-22-000044-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1808805/000180880522000044/naut-20220503.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001808805-22-000044
- JSON: https://secwatch.observer/filing/0001808805-22-000044.json
- Plain text: https://secwatch.observer/filing/0001808805-22-000044.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.